As advised via PHARMAC tender of 31 October 2018 there is to be a change in the listing and future sole supply.

New listing from 1 March 2019

Valganciclovir Myan Tab 450 mg 60                            Pharmacode 2558491                            Schedule price $225.00

Incumbent brand

Valcyte Tab 450 mg 60                                                     Pharmacode            2084767                    Schedule price $1050.00

Reference pricing will apply 1 May 2019.

HSS (Hospital Supply Status) will commence 1 May 2019 and CSS (Community Supply Status) 1 August 2019.

As of the date of this notification ProPharma / PWR cannot accept Valcyte Tab for credit under any circumstances.

We would recommend you continue to purchase the incumbent (while stocks remain available) and we will change automatically as existing stocks are exhausted.

Your margin on the incumbent product is superior to the new product therefore providing you can use stock and claim before application of reference pricing we suggest you do so.

Once again we need your support to ensure stock in the supply chain moves through, to effectively ensure no losses are incurred.

Together we can make this a seamless and painless transition.

We thank you in anticipation of your ongoing support.

About The Author